Vynpenta (previously AvacopanChemoCentryx) (avacopan)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- avacopan
- Company
- ChemoCentryx Ltd
- Status
- Application withdrawn
- Designations
- Orphan
- Application
- EMEA/H/C/004487
- ATC
- L04
- Official record
- www.ema.europa.eu
Indication
Induction of response in adult patients with granulomatosis with polyangiitis (Wegener’s) (GPA) or microscopic polyangiitis (MPA)
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Tavneos Revoked · Vifor Fresenius Medical Care Renal Pharma France
Follow Vynpenta (previously AvacopanChemoCentryx)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.